Here we describe a novel assay for monitoring prion uptake and trafficking by immune cells immediately following intraperitoneal inoculation by purifying and fluorescently labeling aggregated prion rods from infected brain material then monitoring their uptake and movement from the injection site and characterizing the cells mediating these events.
Presence of an abnormal form a host-encoded prion protein (PrPC) that is protease resistant, pathologic and infectious characterizes prion diseases such as Chronic Wasting Disease (CWD) of cervids and scrapie in sheep. The Prion hypothesis asserts that this abnormal conformer constitutes most or all of the infectious prion. The role of the immune system in early events in peripheral prion pathogenesis has been convincingly demonstrated for CWD and scrapie 1-3. Transgenic and pharmacologic studies in mice revealed an important role of the Complement system in retaining and replicating prions early after infection 4-6. In vitro and in vivo studies have also observed prion retention by dendritic cells 7-10, although their role in trafficking remains unclear 11-16. Macrophages have similarly been implicated in early prion pathogenesis, but these studies have focused on events occurring weeks after infection 3,11,17. These prior studies also suffer from the problem of differentiating between endogenous PrPC and infectious prions. Here we describe a semiquantitative, unbiased approach for assessing prion uptake and trafficking from the inoculation site by immune cells recruited there. Aggregated prion rods were purified from infected brain homogenate by detergent solubilization of non-aggregated proteins and ultracentrifugation through a sucrose cushion. Polyacrylamide gel electrophoresis, coomassie blue staining and western blotting confirmed recovery of highly enriched prion rods in the pelleted fraction. Prion rods were fluorochrome-labeled then injected intraperitoneally into mice. Two hours later immune cells from peritoneal lavage fluid, spleen and mediastinal and mesenteric lymph nodes were assayed for prion rod retention and cell subsets identified by multicolor flow cytometry using markers for monocytes, neutrophils, dendritic cells, macrophages and B and T cells. This assay allows for the first time direct monitoring of immune cells acquiring and trafficking prions in vivo within hours after infection. This assay also clearly differentiates infectious, aggregated prions from PrPC normally expressed on host cells, which can be difficult and lead to data interpretation problems in other assay systems. This protocol can be adapted to other inoculation routes (oral, intravenous, intranervous and subcutaneous, e.g.) and antigens (conjugated beads, bacterial, viral and parasitic pathogens and proteins, egg) as well.
1. Purifying and Labeling Prion Rods
This protocol is adapted from one previously published 18
2. Prion Inoculation and Cell Recovery
This section encompasses intraperitoneal prion inoculation and recovery of cells from the peritoneum, mediastinal and mesenteric lymph nodes and spleen.
3. Cell Staining and Flow Cytometry
The following is a typical staining protocol for identifying immune cell subsets using fluorescent antibodies against well-characterized immune cell surface markers. All antibodies were diluted into FACS buffer immediately before use.
4. Representative Results:
We purified prion rods from crude, prion-infected brain homogenate (Figure 1) Detergent solubilization and ultracentrifugation of the E2 elk brain homogenate (lanes 1 and 2) greatly enriched for prion rods (compare lanes 1 and 3), which was also protease K resistant (lane 4). Interestingly, undigested purified prion rods displayed a glycoform profile strikingly similar to digested E2 brain homogenate, indicating dramatic enrichment for prions. Identically-treated normal brain homogenate produced no PK-resistant PrPC (lanes 5 and 6).
Flow cytometric analysis of specific cell populations demonstrate that antigen presenting cells home to the peritoneum by two hours and retain fluorescent beads and prion rods, as evidenced by dramatically increased fluorescence over PBS injected controls (Figure 2). No cells harvested from the peritoneum of PBS-treated controls displayed fluorescence above background (Figs. 2A-G), while cells from bead (Figs. 2H-N) and prion (Figs. 2O-U)-inoculated mice displayed significant fluorescence, especially on monocytes (Figs. 2I and P), dendritic cells (Figs. 2K and R) and macrophages (Figs. 2L and S), and some Neutrophils (Figure 2J and Q) and fewer B cells (Figure 2T). Bead and Prion-bearing monocytes, dendritic cells and macrophages were also found in the mediastinal lymph nodes two hours after inoculation (Figs. 2AD and AK, AF and AM and AG and AN, respectively), while few or no PrPCWD-bearing Neutrophils, B or T cells were found there (Figs. 2AE and AL, AH and AG and AI and AP, respectively). We detected no beads or prion rods in the spleen or mesenteric lymph nodes (data not shown). In toto, these data demonstrate that immune cells traffic prions very similarly to other particulate antigens.
REAGENT | FLUOROCHROME | EXCITATION LASER (nm) | PEAK EMISSION (nm) |
Prion rods | DyLight 649 | 633 | 674 |
1 μm beads | AlexaFluor 660 | 633 | 685 |
Antibodies | |||
CD11b | eFluor 450 | 405 | 450 |
Phycoerythrin-Cy7 | 488 | 760 | |
CD11c | R-Phycoerythrin | 488 | 575 |
Phycoerythrin-Cy7 | 488 | 760 | |
Ly6C | Fluoroisothiocyante | 488 | 518 |
Ly6G | R-Phycoerythrin | 488 | 575 |
CD21 | DyLight 488 | 488 | 518 |
B220 | Allophycocyanin-Cy7 | 633 | 785 |
CD3 | R-Phycoerythrin | 488 | 575 |
Table 1. Spectral properties of fluorescent reagents
Figure 1. Purification of prion rods from infected brain homogenate. We used a 10% crude brain homogenate from a CWD-infected deer (E2, lanes 1and 2) as starting material from which we purified aggregated prion rods (lanes 3 and 4). Both crude and purified materials showed characteristic resistance to protease K treatment (lanes 1 – 4), whereas normal brain homogenate does not (lanes 5 and 6). Molecular weight markers are shown in Kd to the left of the blot. BH, brain homogenate.
Figure 2. Flow cytometric analysis of immune cells trafficking prions from the peritoneum to mediastinal lymph nodes two hours after inoculation. PBS (panels A-G and V-AB), fluorescent beads (H-N and AC-AI) or Prion rods (O-U and AJ-AP) were injected into the peritoneum of mice and cells harvested from peritoneal lavage fluid (A-U) or mediastinal lymph nodes (V-AP) two hours later. Graphs in the first column show cells from mice treated with PBS (panels A and V), fluorescent beads (panel H and AC) and prion rods (panels O and AJ). Fluorescent cells (red or green dots) and total cells (grey dots) are plotted to show relative size (forward scatter), granularity (side scatter) and proportion of total live cells that fluoresce. Significant numbers of cells characteristic of granulocytes retained fluorescent beads and rods. Cells were also stained with antibodies against immune cell surface markers and gated for LyG- Ly6C+ monocytes (panels B, I, P, W, AD and AK), Ly6c- CD11c- CD11b+ Ly6G+ neutrophils (C, J, Q, X, AE and AL), Ly6G- Ly6C- CD11b+ CD11c+ dendritic cells (D, K, R, Y, AF and AM), Ly6G- Ly6C- CD11c- CD11b+ macrophages, (E, L, S, Z, AG and AN), CD3-B220+CD21+ B-cells (F, M, T, AA, AH and AO) and CD21-B220- CD3+ T cells (G, N, U, AB, AI and AP). Monocytes, dendritic cells and macrophages retained fluorescent beads and prion rods in the peritoneal cavity (panels I and P, K and R and L and S, respectively) and transported them to mediastinal lymph nodes (panels AD and AK, AF and AM and AG and AN, respectively), demonstrating similar uptake and trafficking of these two particulates. Neutrophils retained a significant amount of beads (J) and fewer rods (Q), but failed to deliver them to lymph nodes (AE and AL). B cells retained and transported some rods (T and AO) but virtually no beads (M and AH). T cells trafficked neither beads nor rods (N, U, AI and AP).
Here we demonstrate a protocol for tagging and tracking prions in vivo that greatly facilitates monitoring early events in peripheral prion infection. This protocol greatly improves on past attempts at monitoring prion uptake in vitro 9 and in vivo 3,12 by pre-labeling highly enriched prion inoculum to unambiguously differentiate it from endogenous PrPC. Because infectious prions and PrPC share the same primary amino acid sequence, generating prion-specific antibodies has been problematic. We have performed similar experiments using PrP null mice injected with PK-digested and methanol precipitated crude brain homogenate that we tracked using Dylight 649-labelelled anti-PrP antibodies (our unpublished data). These experiments produced nearly identical results as shown here, but PrP null mice are not commercially available, not susceptible to prion disease 19 and lack the only bona fide prion receptor known, PrPC. This protocol allows the use of common laboratory mouse strains that express endogenous PrPC, obviating potential problems using PrP null mice.
The data shown here indicates that immune cells capture and traffic prions and fluorescent beads similarly, although B cells were identified as trafficking the former but not the latter. This corroborates previous studies implicating B cells as prion traffickers 6. However, our highly enriched prion preparation likely contains minute quantities of additional labeled proteins, so we cannot rule out the possibility that immune cells traffic these proteins too. Whether very small amounts of contaminating proteins alter prion trafficking or mimics the true biological scenario remains to be determined.
Successful monitoring of immune cells trafficking two different particulates further suggests that this protocol can be adapted to a wide variety of antigens that can be tagged and tracked, such as parasites, bacteria, viruses and proteins.
When performing ultracentrifugation steps in this protocol, large sample volumes can be aliquoted to smaller ones for convenient centrifugation as long as ratios remain constant. For example, instead of layering 100 mL of sample over 900 mL sucrose, one could layer 10 mL over 90 mL in separate tubes, then centrifuge.
Elevating the mouse posteriorly during inoculations moves peritoneal organs anteriorly, minimizing accidental needle injury to them. Slowly and carefully insert needles when inoculating mice and injecting and aspirating PBS from the peritoneum to avoid rupturing this delicate membrane.
When dissecting mice, take care to cut only though the skin in the initial incisions, leaving the thin membrane covering the peritoneum and mediastinum intact, to avoid cutting blood vessels and organs that may interfere with lymph node identification and retrieval.
Lymph nodes can be difficult to identify initially, often looking like adipose tissue. Lymph nodes appear nearly round, off-white to cream-colored and firmer than adipose tissue. These become much easier to identify with practice. Pool lymph nodes from at least two mice to recover enough cells for flow cytometric analyses.
For simultaneously identifying multiple cell surface markers, we strongly recommend using fluorescent antibodies over unlabeled antibodies that require a secondary fluorescent anti-isotype antibody for detection, as the latter experimental design requires careful selection of antibodies generated from multiple species and many more additional control samples.
The authors have nothing to disclose.
We thank Steve McBryant and Jeff Hansen for help with ultracentrifugation and Patti Kiser for help with mouse handling. The National Institute of Neurological Diseases and Stroke at the National Institutes of Health, grant 5R01NS056379-02 funded this work.
Material Name | Type | Company | Catalogue Number | Comment |
---|---|---|---|---|
CWD-infected elk brain | Private elk farm in Colorado | Use any non-human prion-infected brain | ||
Blender | Oster | 6694-015 | Use any commercial blender | |
Centrifuge | Sorvall | SS34 rotor | Use any centrifuge /rotor that can reach 3000 x g and hold ≥ 500 ml volumes | |
Ultracentrifuge | Beckman | 50.2 Ti rotor | Use any ultracentrifuge /rotor that can reach 100,000 x g and hold ≥ 500 ml volumes | |
Bradford Reagent | Sigma-Aldrich | B6916 | ||
Complete mini protease inhibitor cocktail | Roche | 11 836 170 001 | ||
Sonicator | Misonix | MP4000X | Use any horn or probe sonicator set to ~70% max power | |
DyLight antibody Labeling kit | Thermo Scientific | 53050 | ||
microcentrifuge | Eppendorf | 55430R | Use any refrigerated microcentrifuge that can achieve 13,000x g | |
centrifugal filter columns | Millipore | Microcon YM-100 | Use any filter or dialysis membrane with 100 Kd molecular weight cutoff | |
8-40 week-old FVB mice | Charles River | 207 | Use any inbred mouse strain | |
1 μm red fluorescent beads | Phosphorex | 2307 | Use any fluorescent bead ≤ 10 μm | |
RPMI 1640 medium | Invitrogen | 11875-093 | ||
40 μm cell strainer | Falcon | 352340 | ||
fluorescent antibodies | BD pharmingen | Various | Use any fluorescent antibody appropriate for your application. | |
flow cytometer | Dakocytomation | CyanADP | Use any flow cytometer capable of multicolor fluorescence detection |